'The unexpected finding that vaccination-only participants showed superior cross-neutralization compared to individuals with hybrid immunity challenges conventional assumptions about hybrid immunity advantages'.
www.medrxiv.org/content/10.1...
Antibody responses to SARS-CoV-2 variants LP.8.1, LF.7.1, NB.1.8.1, XFG and BA.3.2 following KP.2 monovalent mRNA vaccination
The evolution of SARS-CoV-2 has resulted in antigenically distinct variants that challenge vaccine-induced immunity. The KP.2 monovalent mRNA vaccine was deployed in 2024 to address immune escape by e...